Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The identification of four Consensus Molecular Subtypes (CMS1-4) of colorectal cancer forms a new paradigm for the design and evaluation of subtype-directed therapeutic strategies. The most aggressive subtype - CMS4 - has the highest chance of disease recurrence. Novel adjuvant therapies for patients with CMS4 tumours are therefore urgently needed. CMS4 tumours are characterized by expression of mesenchymal and stem-like genes. Previous pre-clinical work has shown that targeting Platelet-Derived Growth Factor Receptors (PDGFRs) and the related KIT receptor with imatinib is potentially effective against mesenchymal-type colon cancer. In the present study we aim to provide proof for the concept that imatinib can reduce the aggressive phenotype of primary CMS4 colon cancer. METHODS: Tumour biopsies from patients with newly diagnosed stage I-III colon cancer will be analysed with a novel RT-qPCR test to pre-select patients with CMS4 tumours. Selected patients (n = 27) will receive treatment with imatinib (400 mg per day) starting two weeks prior to planned tumour resection. To assess treatment-induced changes in the aggressive CMS4 phenotype, RNA sequencing will be performed on pre- and post-treatment tissue samples. DISCUSSION: The development of effective adjuvant therapy for primary colon cancer is hindered by multiple factors. First, new drugs that may have value in the prevention of (early) distant recurrence are almost always first tested in patients with heavily pre-treated metastatic disease. Second, measuring on-target drug effects and biological consequences in tumour tissue is not commonly a part of the study design. Third, due to the lack of patient selection tools, clinical trials in the adjuvant setting require large patient populations. Finally, the evaluation of recurrence-prevention requires a long-term follow-up. In the ImPACCT trial these issues are addressed by including newly diagnosed pre-selected patients with CMS4 tumours prior to primary tumour resection, rather than non-selected patients with late-stage disease. By making use of the pre-operative window period, the biological effect of imatinib treatment on CMS4 tumours can be rapidly assessed. Delivering proof-of-concept for drug action in early stage disease should form the basis for the design of future trials with subtype-targeted therapies in colon cancer patients. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02685046 . Registration date: February 9, 2016.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623 · cited 1×
“However, microsatellite instability is currently the only molecular marker that is being used in the clinical decision process for adjuvant chemotherapy in colon cancer [22].”
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Sadanandam, A., Lyssiotis, C. A., Homicsko, K., Collisson, E. A., Gibb, W. J., Wullschleger, S., Ostos, L. C. G., Lannon, W. A., Grotzinger, C., Del Rio, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3175 · Cited by 960
De Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771
Ubink, I., Elias, S. G., Moelans, C. B., Laclé, M. M., van Grevenstein, W. M. U., van Diest, P. J., Borel Rinkes, I. H. M., & Kranenburg, O. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw303 · Cited by 40
Self-citation
Cited by
ten Hoorn, S., de Back, T. R., Sommeijer, D. W., & Vermeulen, L. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab106 · Cited by 203
“Other reasons for exclusion after full-text screening were no outcome data of interest reported (n1⁄4 12) (7,42–50), no data on the individual CMSs reported (n1⁄4 3) (51–53), or a study protocol (n1⁄4 1) (54) (Figure 1).”
BackgroundThe tumour–stroma ratio in colon cancer: the biological role and its prognostic impact
van Pelt, G. W., Sandberg, T. P., Morreau, H., Gelderblom, H., van Krieken, J. H. J. M., Tollenaar, R. A. E. M., & Mesker, W. E. (2018) · Histopathology · doi:10.1111/his.13489 · Cited by 155
Peters, N. A., Constantinides, A., Ubink, I., van Kuik, J., Bloemendal, H. J., van Dodewaard, J. M., Brink, M. A., Schwartz, T. P., Lolkema, M. P. J. K., Lacle, M. M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969855 · Cited by 35
Self-citationKüçükköse, E., Peters, N. A., Ubink, I., van Keulen, V. A. M., Daghighian, R., Verheem, A., Laoukili, J., & Kranenburg, O. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05078-z · Cited by 18
“The effect of Imatinib treatment on CMS4 CRC was assessed in the clinical proof-of-concept study ImPACCT, in which patients with newly-diagnosed CMS4 CRC were treated with imatinib two weeks prior surgery [6, 33].”
Self-citation
Metadata
- Authors
- Ubink, I., Bloemendal, H. J., Elias, S. G., Brink, M. A., Schwartz, M. P., Holierhoek, Y. C. W., Verheijen, P. M., Boerman, A. W., Mathijssen, R. H. J., de Leng, W. W. J., de Weger, R. A., van Grevenstein, W. M. U., Koopman, M., Lolkema, M. P., Kranenburg, O., & Borel Rinkes, I. H. M.
- Venue
- BMC Cancer
- Published
- 2017-04-19
- Volume
- 17
- Issue
- 1
- Pages
- 282-282
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2605932962
- Cited by
- 14
- References
- 5
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT). https://app.cochat.ai/papers/10.1186/s12885-017-3264-y
- The paper
- Ubink, I., Bloemendal, H. J., Elias, S. G., Brink, M. A., Schwartz, M. P., Holierhoek, Y. C. W., Verheijen, P. M., Boerman, A. W., Mathijssen, R. H. J., de Leng, W. W. J., de Weger, R. A., van Grevenstein, W. M. U., Koopman, M., Lolkema, M. P., Kranenburg, O., & Borel Rinkes, I. H. M. (2017). Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT). BMC Cancer. https://doi.org/10.1186/s12885-017-3264-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.